Overview

Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy

Status:
Unknown status

Trial end date:
2017-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to identify the effect of prophylactic entecavir in HBsAg Positive lymphoma patients treated with rituximab-based immunochemotherapy.

Phase:

Phase 4

Details

Lead Sponsor:

Peking University

Treatments:

Entecavir
Rituximab